Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | TDP2 | O95551 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.31 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.31 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.31 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764553 | 0.83 | CRBN (0.59) | CRBNJAK2JAK1TYK2JAK3 | |
| SCHEMBL12595090 | 0.81 | CRBN (0.45) | CRBNJAK2JAK1TYK2JAK3 | |
| SCHEMBL1530799 | 0.76 | CRBN (0.65) | CRBNTDP2ROCK2TP53HTR7 | |
| SCHEMBL17374986 | 0.73 | CRBN (0.49) | CRBNTDP2ROCK2TP53HTR7 | |
| SCHEMBL17375035 | 0.73 | CRBN (0.50) | CRBNTDP2ROCK2TP53HTR7 | |
| SCHEMBL17375018 | 0.73 | CRBN (0.48) | CRBNTDP2ROCK2TP53HTR7 | |
| SCHEMBL17378786 | 0.71 | CRBN (0.46) | CRBNHTR7HTR6BRD4 | |
| SCHEMBL17378918 | 0.71 | CRBN (0.46) | CRBNROCK2HTR7HTR6 | |
| SCHEMBL483387 | 0.69 | CRBN (0.67) | CRBNTDP2ROCK2TP53BRD4 | |
| SCHEMBL11996547 | 0.68 | CRBN (0.40) | CRBNTDP2ROCK2HTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | claimed |
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123490-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RRM2B, POLR2A, RRM2 | CRBN 1400/4885JAK2 370/4885JAK1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.